TNX-102 SL
TNX-CY-P301
Phase 3 small_molecule terminated
Quick answer
TNX-102 SL for PTSD is a Phase 3 program (small_molecule) at Tonix Pharmaceuticals Holding with 6 ClinicalTrials.gov record(s).
Program details
- Company
- Tonix Pharmaceuticals Holding
- Indication
- PTSD
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated